CLINICAL ROLE -
Pre-Chemo Enzalutamide Approved for Metastatic Castration-Resistant Prostate Cancer
The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
Read More
FDA Approves Neoadjuvant Pertuzumab Regimen
Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.